ValuEngine cut shares of Windtree Therapeutics (OTCMKTS:WINT) from a buy rating to a hold rating in a report released on Thursday, ValuEngine reports.

Shares of OTCMKTS WINT remained flat at $$4.10 during midday trading on Thursday. 1,523 shares of the stock were exchanged, compared to its average volume of 980. The firm has a fifty day moving average of $4.05 and a 200 day moving average of $3.77. The stock has a market cap of $168.43 million, a PE ratio of -1.06 and a beta of 0.23. The company has a quick ratio of 0.32, a current ratio of 0.32 and a debt-to-equity ratio of 0.30. Windtree Therapeutics has a fifty-two week low of $2.04 and a fifty-two week high of $4.99.

Windtree Therapeutics (OTCMKTS:WINT) last announced its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter. Windtree Therapeutics had a negative return on equity of 48.08% and a negative net margin of 3,548.97%.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant.

Further Reading: How to build a Fibonacci channel

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.